FDA approved Priovant's Lisraya (brepocitinib) as the first targeted therapy for dermatomyositis, Gilead's Bixlenvo as the ...
FDA approves three new therapies spanning autoimmune disease, HIV, and cardiovascular risk, DualityBio and Teva strike major ...
With biopharma batch failures averaging every 40 weeks, predictive maintenance and connected monitoring are becoming critical ...
Osivax and GC Biopharma team up on a next-generation flu vaccine, K2 Therapeutics' Ying Huang talks through why so few drugs ...
DualityBio has licensed its Dupac next-generation ADC payload platform to Genentech, and Teva has entered a stalking horse bid to acquire BioXcel's Igalmi. Dealmaking activity spanned oncology and ...
Due the nature of the technology, various companies have implemented it across multiple sectors. Now, the question that everyone is asking is: where is AI having an actual impact? In March of this ...
ACTO CEO Parth Khanna on why sales reps still matter — and how human intelligence plus empathetic agents is the winning formula for field teams.
President Donald Trump’s administration is preparing to announce a new round of drug-pricing agreements with midsize biotech ...
Eli Lilly and Company announced results from a real-world study of adults over 55 with obesity or overweight showing that ...
The FDA has approved daraxonrasib (brand name Rasonque) for adults with metastatic pancreatic adenocarcinoma who have ...
A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike major ...
Pharmaceutical Executive spoke with K2 Therapeutics’ CEO Dr. Ying Huang about the growing shift towards globally sourced innovation and the increased focus on foreign partnerships. The push has become ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results